Commentary: One nano-step for murinekind, one giant leap for mesothelioma

Our plain-English summary of Commentary: One nano-step for murinekind, one giant leap for mesothelioma, by J.S. Dutcher, J. D'Cunha (The Journal of Thoracic and Cardiovascular Surgery, 2020).

The study

• Authors: J.S. Dutcher, J. D'Cunha
• Journal: The Journal of Thoracic and Cardiovascular Surgery
• Published: 2020;160(3):e170-e171
• Type of article: Editorial, Comment
• Read it: PubMed · Publisher

In plain English

This article is a two-page commentary, not an original study. The authors, from the Department of Cardiothoracic Surgery at Mayo Clinic Arizona, discussed a separate study by Chu and colleagues. That study tested paclitaxel-loaded expansile nanoparticles (PTX-eNPs), a way of delivering the chemotherapy drug paclitaxel into the chest cavity, in mice implanted with human malignant pleural mesothelioma cells. The cells were the MSTO-211H cell line, which the commentary describes as an aggressive variant of biphasic mesothelioma. According to the commentary, that study found the nanoparticle delivery in the chest cavity feasible, safe, and superior to conventional systemic chemotherapy in mouse models of both limited and advanced-stage disease. It also found that the nanoparticles enhanced the effect of cytoreductive (tumor-removing) surgery. The commentary did not study asbestos exposure or human patients. The authors suggested that, because paclitaxel is not a first-line mesothelioma drug, the way the drug is delivered may be the key issue. They called for more work on how the effect arises and for testing nanoparticles that carry current first-line drugs.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Commentary (invited editorial) on another study published in the same journal; not original research
• Who was studied: No population was studied in this commentary. The study it discusses (Chu and colleagues) used mice (xenograft models) implanted with the human mesothelioma cell line MSTO-211H, described as an aggressive variant of biphasic human mesothelioma.
• Exposure: Not an asbestos exposure. The study discussed tested a treatment: paclitaxel-loaded expansile nanoparticles (PTX-eNPs) delivered in the thoracic cavity, compared with conventional systemic chemotherapy, in mice with malignant pleural mesothelioma.
• Main results:
  • The commentators report that the study by Chu and colleagues (not this commentary) found that PTX-eNP drug delivery in the thoracic cavity was feasible, safe, and superior to conventional systemic chemotherapy in mouse models of both limited and advanced-stage malignant pleural mesothelioma.
  • The commentators report that, in Chu and colleagues' study, PTX-eNPs worked together with cytoreductive surgery in mice and enhanced its efficacy.
  • The commentators note that the same research group had earlier found markedly increased antitumor results using a similar method in intraperitoneal mesothelioma (a separate, earlier study).
• The authors' conclusion: The authors suggested that, because the results were obtained with paclitaxel, which is not a first-line treatment for malignant pleural mesothelioma, drug delivery may be the real issue. They called for further study of the mechanism and for comparison with nanoparticles that carry current first-line drugs.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Mesothelioma.

Related studies

• Commentary: Local chemotherapy with nanoparticles: A ray of light in the dark? — S. Nakamura, T.F. Chen-Yoshikawa (2020)
• Commentary: Go small or go home — A.W. Kim, U. Ahmad (2020)
• Predicting EMP hazard: Lessons from studies with inhaled fibrous and non-fibrous nano- and micro-particles — G. Oberdörster, U. Graham (2018)
• Metal load assessment in patient pulmonary lavages: towards a comprehensive mineralogical analysis including the nano-sized fraction — V. Forest, J.M. Vergnon, et al. (2017)
• Commentary: A journey of a thousand miles begins with a single step — T.F. Chen-Yoshikawa (2020)
• Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma — R. Liu, A.H. Colby, et al. (2016)

Browse more research in The Journal of Thoracic and Cardiovascular Surgery, or return to medical research.